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(range 0–49). The median survival time for the whole series was 8.3 months (IC 95%, 6–10) and 38% of patients were still alive at
1 year after diagnosis. There were statistically signiﬁcant differences between those patients who completed RT (13 months (IC
95%, 9–16)) and not completed RT ((4 months (IC 95%, 3–5)), p=0.0001; and between patients treated with RT (5 months (IC 95%,
4–6)) and those receiving combined therapy (15 months (IC 95%, 14–17)), p=0.0001.
Conclusion. Our data conﬁrm that the administration of concurrent RT and TMZ helps to prolong survival for patients with HGG.
http://dx.doi.org/10.1016/j.rpor.2013.03.144
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Material and methods. We analyzed 193 patients treated between 1999 and 2012. The average age 53.2 years, 119 males and 74
females, KS=100:64.2%, KS=90:27.5% and KS=80:8.3%.
Initial symptom. Motor impairment 31.6%, seizure 27.5%, headache 25.9% and other 14.5%.
Surgery. Complete 41.5%, partial excision 43.5% and 15% biopsy. AP:GBM85%, astrocitoma anaplasic AA 13.5%, and other histology
6%.
Treatment. Temozolamine was given as concomitant and adjuvant, 6 or more cycles if tumour remains or progression in 63.7%,
concomitant 20.7% and only adjuvant in 15.6%. Since 2003, carmustine implants were associated +/− RT+/−TMZ at 26.1%.
Results. High overall response rate at the end of treatments: CR 42.3%, PR 21.4%, PE 23.6% and EE 12.6%. A total of 82.8%recurrences
and 17.2% without relapse. Kaplan–Meier average: median overall survival (OS) was 25.8 months (CI 22–29.7), median survival at
16 months (CI 13.4–18.5). OS rate of 61.5%, 32%, 22.6%, 17.5%, 11.7%, 4.1% at 1, 2, 3, 4, 5 and 10 years and respectively. Remain
alive 19.7% (85 months of follow-up). Mean recurrence-free survival (RFS) 11.6 (CI 10–13.2), median 8 months (CI 6.6–9.3). SLR rate
of 30.1%, 10.3%, 2.1%, 0.7%, 0% at 1, 2, 3, 4 and 5 years respectively. In univariate survival analysis for OS the AA histology, age
(<60 years), KS, QT regimen administered (concomitant and adjuvant), and treatment response was signiﬁcant favorable and the
SLR was signiﬁcant in age and KS. On the other hand, was not signiﬁcant the delay on start RT from the surgery and the delay
in the duration of RT in OS or SLR.
Conclusion. Our series reaches a survival rate of 61–11% in 1–5 years, with better outcomes in prognostic factors of OS the age, KS,
histology, QT regimen administrated and the response achieved.
http://dx.doi.org/10.1016/j.rpor.2013.03.145
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Craniospinal irradiation is one of the most challenging radiotherapy techniques. More than one isocenter is needed to cover
the total PTV length, thus creating junction lines and potentially causing over- or under-dosiﬁcation. The aim of this work
is to present our experience with a medulloblastoma case treated with VMAT. The prescribed dose to craniospinal axis was
36Gy (1.8Gy/f) and a boost of 18Gy (1.8Gy/f) to the posterior fossa. The patient was immobilized with head plastic mask and
vacuum bag in supine position. The total PTV length was 79.5 cm. Our VMAT craniospinal technique consisted of three isocenters
located at the center of the head, sixth thoracic vertebra and second lumbar vertebra, respectively. An overlap region was
intentionally created, ranging 2–5 cm, to better control the dose and avoid junction lines. Dailyc Cone Beam CT was programmed
for each isocenter before treatment. For dose comparison purposes, a 3D conformal radiotherapy (3DCRT) plan with 2 isocenters
and daily junction line shift was generated, and literature data with tomotherapy (TX) was used. The PTV dose coverage is
similar, although 3DCRT had worse dose homogeneity. Regarding the organs at risk, medially located organs receive higher
mean dose with 3DCRT, whilst sideways organs receive higher mean dose with both volumetric techniques. The mean dose
with VMAT/TX/3DCRT for different organs is presented, heart: 4.9/11.0/15.3Gy; liver: 6.2/8.0/4.3Gy; lungs: 8.1/6/2.8Gy; kidneys:
6.4/6.5/1.2Gy; thyroids: 9.5/25/27.2Gy; eyes: 10.8/13.3/naGy; larynx: 15.0/28.3/naGy; body 8.1/6.9/10.0Gy. The total treatment time
per fraction is around 30min, 15min for patient positioning, CBCT acquisition and analysis, and 15min for irradiation, lower
than the 45min time reported with tomotherapy for a similar patient. Concluding, VMAT is a safe, fast and accurate technique
for craniospinal irradiation, comparable with tomotherapy, avoiding the junction line problem of 3DCRT.
http://dx.doi.org/10.1016/j.rpor.2013.03.146
